Tsunenori Kondo

50PUBLICATIONS
31CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyPredictive and prognostic markersRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (50)

|Jun 15, 2026
Future direction of systemic therapy for advanced renal cell carcinoma: lessons from final and extended follow-up data from the CheckMate 9ER trial.

|May 07, 2026
Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma.

|Mar 02, 2026
Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma.

Hiroki Ishihara, Koichi Nishimura, Yuki Nemoto

|Feb 16, 2026
Impact of Cytoreductive Nephrectomy on Immune Checkpoint Inhibitor Therapy: Treatment Outcomes of Immune Inhibitors Combination Therapies for Metastatic Renal Cell Carcinoma With Primary Kidney Tumors.

Yuki Nemoto, Hiroki Ishihara, Hironori Fukuda

|Jan 27, 2026
Non-Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors.

Hiroki Ishihara, Yu-Yu Liu, Riu Yamashita

|Dec 18, 2025
Outcomes of tyrosine kinase inhibitor monotherapy for advanced renal cell carcinoma arising in patients with kidney transplantation: comparison with sporadic and end-stage renal disease populations.

Nanaka Katsurayama, Hiroki Ishihara, Toshihito Hirai

Pageof 9

Frequent Collaborators

22 joint publications

Toshio Takagi

13 joint publications

Kazuhiko Yoshida

7 joint publications

Tsunenori Kondo

2 joint publications

Toshikazu Ushijima